Literature DB >> 17401348

Protocol for the MPTP mouse model of Parkinson's disease.

Vernice Jackson-Lewis1, Serge Przedborski.   

Abstract

This protocol describes our method of producing a reliable mouse model of Parkinson's disease (PD) using the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We discuss the particulars of the model, provide key references and outline what investigators need to know to develop the MPTP mouse model of PD safely and successfully. Completion of this protocol depends on the regimen of MPTP used and on the actual planned studies, which often range from 7 to 30 d. This protocol calls for implementation of safety measures and for the acquisition of several pieces of equipment, which are a one-time investment worth making if one elects to use this model on a regular basis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401348     DOI: 10.1038/nprot.2006.342

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  324 in total

1.  CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.

Authors:  Mikko Airavaara; Brandon K Harvey; Merja H Voutilainen; Hui Shen; Jenny Chou; Päivi Lindholm; Maria Lindahl; Raimo K Tuominen; Mart Saarma; Barry Hoffer; Yun Wang
Journal:  Cell Transplant       Date:  2011-09-22       Impact factor: 4.064

2.  Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.

Authors:  Eleni Antzoulatos; Michael W Jakowec; Giselle M Petzinger; Ruth I Wood
Journal:  Pharmacol Biochem Behav       Date:  2010-03-27       Impact factor: 3.533

3.  Recombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxin.

Authors:  Ravindar R Thomas; Shaharyar M Khan; Francisco R Portell; Rafal M Smigrodzki; James P Bennett
Journal:  Mitochondrion       Date:  2010-08-18       Impact factor: 4.160

4.  Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine.

Authors:  Kimberly A Kelly; Diane B Miller; John F Bowyer; James P O'Callaghan
Journal:  J Neurochem       Date:  2012-08-03       Impact factor: 5.372

5.  Preferential Heme Oxygenase-1 Activation in Striatal Astrocytes Antagonizes Dopaminergic Neuron Degeneration in MPTP-Intoxicated Mice.

Authors:  Xiaofeng Xu; Ning Song; Ranran Wang; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2015-09-18       Impact factor: 5.590

6.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

7.  MPP(+) -dependent inhibition of Ih reduces spontaneous activity and enhances EPSP summation in nigral dopamine neurons.

Authors:  A Masi; R Narducci; E Landucci; F Moroni; G Mannaioni
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice.

Authors:  Lisa M Kosloski; Elizabeth A Kosmacek; Katherine E Olson; R Lee Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2013-10-29       Impact factor: 3.478

9.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

10.  Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.

Authors:  Hiroharu Maegawa; Hitoshi Niwa
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.